115729-52-7

Usage

Uses

Used in Pharmaceutical Industry:
Enalapril diketopiperazine is used as an impurity reference substance for the quality control and assurance of Enalapril (E555250). It helps in the identification, quantification, and control of impurities in the active pharmaceutical ingredient (API), ensuring the safety and efficacy of the final drug product.
Used in Research and Development:
Enalapril diketopiperazine is utilized as a research compound in the development of new drugs and therapies related to high blood pressure and heart failure. It aids in understanding the chemical properties, interactions, and potential side effects of Enalapril, contributing to the advancement of medical knowledge in this field.

Upstream product

• 84793-24-8 N-[1-(S)-ethoxycarbonyl-3-phenylpropyl]-L-alanine N-carboxyanhydride 
• 147-85-3 L-proline 
• 75847-73-3 enalapril 

Relevant academic research and scientific papers

Stereochemical investigations on the diketopiperazine derivatives of enalapril and lisinopril by NMR spectroscopy

Stereochemical analysis of epimeric diketopiperazine (DKP) derivatives of enalapril and lisinopril has been performed by NMR spectroscopy. The present study focuses on the configurational assignment and conformational characteristics of the epimeric DKPs

Process for preparing pharmacologically acceptable salt of N-(1(S)-ethoxycarbonyl-3-phenylpropyl)-L-alanyl amino acids

There is provided a process for preparing a pharmacologically acceptable salt of N-(1(S)-ethoxycarbonyl-3-phenylpropyl)-L-alanyl-amino acid which comprises condensing an amino acid and N-(1(S)-ethoxycarbonyl-3-phenylpropyl)-L-alanine.N-carboxyanhydride under basic condition, carrying out decarboxylation under between neutral and acidic condition to obtain N-(1(S)-ethoxycarbonyl-3-phenylpropyl)-L-alanyl-amino acid, and forming a pharmacologically acceptable salt thereof, wherein the production of a by-product (3): is suppressed by carrying out in an aqueous liquid a series of operations till formation of the pharmacologically acceptable salt or till isolation of the pharmacologically acceptable salt. The present invention enables to prepare the pharmacologically acceptable salt of N-(1(S)-ethoxycarbonyl-3-phenylpropyl)-L-alanyl-amino acid having high quality, in a commercial scale with high yield and economical efficiency.